Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers N > Headlines for NeoPharm Inc. > News item |
JMP reiterates NeoPharm at strong buy
NeoPharm, Inc. was reiterated by JMP Securities analyst Charles C. Duncan at a strong buy after the company's analyst day highlighted NeoPharm's transition into a commercial-stage biotechnology company. Takeaways from the day include: thorough and clear commercial strategies to bring cintredekin besudotox (CBtox) to the U.S. and EU market, reconfirmation of CBtox's survival improvement in recurrent glioblastoma (GBM) over standard-of-care and a strong focus on growing the NeoLipid platform of products. Shares of the Waukegan, Ill.-based biopharmaceutical company were up 10 cents, or 2.07%, at $4.92. (Nasdaq: NEOL)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.